{"filing":{"accession_number":"0001104659-26-088455","cik":"0001761612","ticker":"BCYC","company_name":"BICYCLE THERAPEUTICS PLC","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"tm2621593d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926088455/tm2621593d1_8k.htm"},"events":[{"id":22043,"run_id":19910,"accession_number":"0001104659-26-088455","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release for Q2 2026 financial results. The filing discloses quarterly financial statements (revenue, R\u0026D expenses, G\u0026A expenses, net loss per share), cash position ($510.1 million), and cash runway projections into 2030. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The financial results are material to investors assessing the company's operational performance and financial health.","company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":21855,"accession_number":"0001104659-26-088455","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 financial results. The filing discloses quarterly financial statements (revenue, R\u0026D expenses, G\u0026A expenses, net loss per share), cash position ($510.1 million), and cash runway projections into 2030. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The financial results are material to investors assessing the company's operational performance and financial health.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T11:09:00.056785+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21855,"accession_number":"0001104659-26-088455","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 financial results. The filing discloses quarterly financial statements (revenue, R\u0026D expenses, G\u0026A expenses, net loss per share), cash position ($510.1 million), and cash runway projections into 2030. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The financial results are material to investors assessing the company's operational performance and financial health.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T11:09:00.056785+00:00","company_name":"BICYCLE THERAPEUTICS PLC","ticker":"BCYC","filing_date":"2026-07-30"}]}